The Impact of Evolving Treatment Options in Multiple Myeloma, Part 5
November 15th 2021Joseph Mikhael, MD, reviews the phase 2 GRIFFIN trial evaluating the use of quadruplet therapy, daratumumab plus VRd, in patients with multiple myeloma, and the panel comments on the use of quadruplet therapy.
Read More
The Impact of Evolving Treatment Options in Multiple Myeloma, Part 2
November 1st 2021Ryan Haumschild, PharmD, MS, MBA, comments on the use of triplet regimens as the standard of care treatment for patients with multiple myeloma, and Thomas Ollis, MS, RPh, shares a community practice perspective.
Read More